Abbott Laboratories Debt to Equity Ratio 2010-2023 | ABT
Current and historical debt to equity ratio values for Abbott Laboratories (ABT) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Abbott Laboratories debt/equity for the three months ending December 31, 2023 was 0.32.
| Abbott Laboratories Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2023-12-31 | $34.39B | $38.83B | 0.89 |
| 2023-09-30 | $34.40B | $37.69B | 0.91 |
| 2023-06-30 | $35.95B | $37.40B | 0.96 |
| 2023-03-31 | $36.56B | $37.23B | 0.98 |
| 2022-12-31 | $37.53B | $36.91B | 1.02 |
| 2022-09-30 | $36.92B | $35.88B | 1.03 |
| 2022-06-30 | $37.49B | $36.72B | 1.02 |
| 2022-03-31 | $38.38B | $35.63B | 1.08 |
| 2021-12-31 | $39.17B | $36.02B | 1.09 |
| 2021-09-30 | $39.16B | $34.64B | 1.13 |
| 2021-06-30 | $39.24B | $34.03B | 1.15 |
| 2021-03-31 | $39.00B | $33.79B | 1.15 |
| 2020-12-31 | $39.55B | $33.00B | 1.20 |
| 2020-09-30 | $37.45B | $31.60B | 1.19 |
| 2020-06-30 | $37.98B | $30.80B | 1.23 |
| 2020-03-31 | $36.35B | $30.43B | 1.20 |
| 2019-12-31 | $36.59B | $31.30B | 1.17 |
| 2019-09-30 | $36.52B | $32.02B | 1.14 |
| 2019-06-30 | $36.53B | $31.89B | 1.15 |
| 2019-03-31 | $36.48B | $31.13B | 1.17 |
| 2018-12-31 | $36.45B | $30.72B | 1.19 |
| 2018-09-30 | $40.74B | $30.90B | 1.32 |
| 2018-06-30 | $37.64B | $30.77B | 1.22 |
| 2018-03-31 | $39.31B | $31.60B | 1.24 |
| 2017-12-31 | $45.15B | $31.10B | 1.45 |
| 2017-09-30 | $40.03B | $32.22B | 1.24 |
| 2017-06-30 | $39.36B | $31.79B | 1.24 |
| 2017-03-31 | $39.34B | $31.55B | 1.25 |
| 2016-12-31 | $31.95B | $20.72B | 1.54 |
| 2016-09-30 | $18.60B | $20.90B | 0.89 |
| 2016-06-30 | $19.04B | $20.80B | 0.92 |
| 2016-03-31 | $18.80B | $20.84B | 0.90 |
| 2015-12-31 | $19.92B | $21.33B | 0.93 |
| 2015-09-30 | $20.51B | $21.22B | 0.97 |
| 2015-06-30 | $21.00B | $23.13B | 0.91 |
| 2015-03-31 | $21.11B | $21.99B | 0.96 |
| 2014-12-31 | $19.57B | $21.64B | 0.90 |
| 2014-09-30 | $19.52B | $22.99B | 0.85 |
| 2014-06-30 | $17.77B | $23.70B | 0.75 |
| 2014-03-31 | $18.17B | $23.49B | 0.77 |
| 2013-12-31 | $17.69B | $25.27B | 0.70 |
| 2013-09-30 | $20.35B | $23.79B | 0.86 |
| 2013-06-30 | $20.48B | $22.43B | 0.91 |
| 2013-03-31 | $20.00B | $22.68B | 0.88 |
| 2012-12-31 | $40.42B | $26.81B | 1.51 |
| 2012-09-30 | $36.15B | $27.10B | 1.33 |
| 2012-06-30 | $37.29B | $24.57B | 1.52 |
| 2012-03-31 | $36.87B | $25.54B | 1.44 |
| 2011-12-31 | $35.75B | $24.53B | 1.46 |
| 2011-09-30 | $34.94B | $24.69B | 1.42 |
| 2011-06-30 | $35.54B | $26.47B | 1.34 |
| 2011-03-31 | $36.93B | $24.72B | 1.49 |
| 2010-12-31 | $37.81B | $22.77B | 1.66 |
| 2010-09-30 | $35.89B | $21.48B | 1.67 |
| 2010-06-30 | $33.39B | $20.00B | 1.67 |
| 2010-03-31 | $32.35B | $21.01B | 1.54 |
| 2009-12-31 | $29.39B | $23.19B | 1.27 |
| 2009-09-30 | $28.47B | $21.38B | 1.33 |
| 2009-06-30 | $27.71B | $19.92B | 1.39 |
| 2009-03-31 | $27.45B | $17.98B | 1.53 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $181.079B | $40.109B |
| Abbott Labs discovers, develops, manufactures & sells a diversified line of health care products. Established Pharmaceuticals Division includes branded generics business in the emerging markets. Medical Devices unit includes the diabetes care, vision care & vascular businesses. Diagnostics unit manufactures and markets diagnostic systems and tests in four business lines core laboratory, molecular, point of care and rapid diagnostics. Nutrition unit includes a broad line of pediatric and adult nutritional products. Abbott acquired CFR Pharmaceuticals, Tendyne Holdings, Inc., St. Jude Medical and Alere Inc. On the other hand, Abbott sold its developed markets branded generics pharmaceuticals business to Mylan. Abbott retained the branded generics pharmaceuticals business in emerging markets. Abbott sold its animal health business to Zoetis Inc and divested its vision care business, Medical Optics, to Johnson & Johnson. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stryker (SYK) | United States | $127.496B | 30.54 |
| Medtronic (MDT) | Ireland | $114.087B | 16.15 |
| Boston Scientific (BSX) | United States | $109.519B | 34.88 |
| EssilorLuxottica (ESLOY) | France | $102.905B | 0.00 |
| Lonza Group Ag (LZAGY) | Switzerland | $43.259B | 0.00 |
| Haleon (HLN) | United Kingdom | $38.858B | 28.37 |
| ResMed (RMD) | United States | $32.109B | 30.15 |
| Koninklijke Philips (PHG) | Netherlands | $25.984B | 20.13 |
| Terumo (TRUMY) | Japan | $25.953B | 36.65 |
| Zimmer Biomet Holdings (ZBH) | United States | $24.724B | 15.79 |
| Baxter (BAX) | United States | $17.963B | 12.77 |
| Insulet (PODD) | United States | $13.116B | 58.16 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $11.406B | 0.00 |
| Demant (WILYY) | Denmark | $10.234B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $8.382B | 27.41 |
| BellRing Brands (BRBR) | United States | $7.488B | 35.22 |
| Lantheus Holdings (LNTH) | United States | $5.522B | 13.76 |
| Haemonetics (HAE) | United States | $4.862B | 24.05 |
| GN Store Nord (GNNDY) | Denmark | $4.400B | 24.71 |
| Perrigo (PRGO) | Ireland | $4.066B | 12.33 |
| Prestige Consumer Healthcare (PBH) | United States | $3.227B | 15.36 |
| Envista Holdings (NVST) | United States | $3.185B | 13.14 |
| Neogen (NEOG) | United States | $2.933B | 28.21 |
| QuidelOrtho (QDEL) | United States | $2.868B | 15.92 |
| Maravai LifeSciences Holdings (MRVI) | United States | $2.846B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $2.735B | 54.17 |
| TG Therapeutics (TGTX) | United States | $2.547B | 71.65 |
| ICU Medical (ICUI) | United States | $2.534B | 22.36 |
| Agios Pharmaceuticals (AGIO) | United States | $1.950B | 0.00 |
| Verano Holdings (VRNOF) | United States | $1.790B | 0.00 |
| LeMaitre Vascular (LMAT) | United States | $1.761B | 51.61 |
| Warby Parker (WRBY) | United States | $1.639B | 0.00 |
| InMode (INMD) | Israel | $1.550B | 8.24 |
| Owens & Minor (OMI) | United States | $1.424B | 12.41 |
| AdaptHealth (AHCO) | United States | $1.329B | 9.88 |
| National Vision Holdings (EYE) | United States | $1.240B | 39.45 |
| AtriCure (ATRC) | United States | $1.101B | 0.00 |
| BioLife Solutions (BLFS) | United States | $1.011B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.913B | 0.00 |
| Evolus (EOLS) | United States | $0.851B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.747B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.745B | 15.86 |
| Quanterix (QTRX) | United States | $0.664B | 0.00 |
| Valneva SE (VALN) | France | $0.618B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.612B | 14.39 |
| PetIQ (PETQ) | United States | $0.588B | 19.20 |
| TerrAscend (TSNDF) | Canada | $0.519B | 0.00 |
| Surmodics (SRDX) | United States | $0.494B | 30.91 |
| Jin Medical (ZJYL) | China | $0.465B | 0.00 |
| ZimVie (ZIMV) | United States | $0.464B | 39.58 |
| Aurora Cannabis (ACB) | Canada | $0.403B | 0.00 |
| Cerus (CERS) | United States | $0.364B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.364B | 11.71 |
| Biote (BTMD) | United States | $0.357B | 8.21 |
| Zynex (ZYXI) | United States | $0.346B | 47.30 |
| Viemed Healthcare (VMD) | United States | $0.276B | 27.35 |
| MacroGenics (MGNX) | United States | $0.273B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.264B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.263B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.246B | 15.49 |
| Organigram Holdings (OGI) | Canada | $0.209B | 0.00 |
| Ayr Wellness (AYRWF) | United States | $0.209B | 0.00 |
| Omeros (OMER) | United States | $0.200B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.197B | 0.00 |
| Veru (VERU) | United States | $0.193B | 0.00 |
| High Tide (HITI) | Canada | $0.175B | 0.00 |
| Eagleford Energy (GRUSF) | United States | $0.171B | 82.00 |
| InterCure (INCR) | Israel | $0.150B | 25.31 |
| Jushi Holdings (JUSHF) | United States | $0.138B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.134B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.128B | 18.14 |
| Cellectar Biosciences (CLRB) | United States | $0.118B | 0.00 |
| Fonar (FONR) | United States | $0.096B | 8.28 |
| MariMed (MRMD) | United States | $0.094B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.093B | 0.00 |
| Brainsway (BWAY) | Israel | $0.090B | 0.00 |
| Chimerix (CMRX) | United States | $0.089B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.085B | 0.00 |
| Zevia PBC (ZVIA) | United States | $0.075B | 0.00 |
| Safety Shot (SHOT) | United States | $0.072B | 0.00 |
| Eagle Pharmaceuticals (EGRX) | United States | $0.062B | 4.03 |
| Apyx Medical (APYX) | United States | $0.055B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.054B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.053B | 0.00 |
| Bright Green (BGXX) | United States | $0.044B | 0.00 |
| United-Guardian (UG) | United States | $0.043B | 15.45 |
| Modular Medical (MODD) | United States | $0.039B | 0.00 |
| ImmuCell (ICCC) | United States | $0.038B | 0.00 |
| Exagen (XGN) | United States | $0.033B | 0.00 |
| Nephros (NEPH) | United States | $0.025B | 0.00 |
| Agape ATP (ATPC) | $0.020B | 0.00 | |
| Meihua Medical Technologies (MHUA) | China | $0.019B | 0.00 |
| Flora Growth (FLGC) | United States | $0.017B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.014B | 0.00 |
| FSD PHARMA (HUGE) | Canada | $0.013B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.012B | 0.00 |
| GUARDION HEALTH (GHSI) | United States | $0.011B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.010B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.008B | 0.00 |
| Leafly Holdings (LFLY) | United States | $0.005B | 0.00 |
| Senestech (SNES) | United States | $0.004B | 0.00 |
| Sharps Technology (STSS) | United States | $0.003B | 0.00 |
| Lucy Scientific Discovery (LSDI) | Canada | $0.003B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.002B | 0.00 |
| Smart For Life (SMFL) | United States | $0.000B | 0.00 |
| Bruush Oral Care (BRSH) | $0.000B | 0.00 | |
| SNDL (SNDL) | Canada | $0.000B | 0.00 |